TScan Therapeutics (TCRX) Cash Flow: Operating & Free Cash Flow

TScan Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for TScan Therapeutics, Inc. (TCRX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Operating Activities
Net Income	-129.77	-127.50	-89.22	-66.22	-48.63	-26.13	-13.66
Depreciation & Amortization	2.87	4.11	5.36	5.14	3.33	1.23	0.52
Deferred Income Tax	0.00	0.00	0.00	0.00	-9.16	0.00	0.00
Stock Based Compensation	11.71	9.55	5.21	4.55	2.52	0.52	0.24
Change in Working Capital	-18.18	5.05	17.61	-10.23	-5.90	21.36	0.30
Change in Accounts Payable	-3.01	1.99	-0.05	0.53	0.01	1.13	0.16
Change in Other Working Capital	-15.17	0.77	17.66	-2.46	-2.60	0.79	0.14
Other Operating Activities	-1.95	0.77	-0.32	0.26	9.16	0.52	0.08
Net Cash from Operating Activities	-135.32	-110.82	-61.36	-66.50	-48.68	-3.02	-12.52
Investing Activities
Capital Expenditures	-4.41	-3.83	-3.15	-4.23	-9.94	-4.24	-1.25
Purchases of Investments	-87.47	-241.45	-77.61	0.00	0.00	0.00	0.00
Sales/Maturities of Investments	201.25	192.66	20.00	0.00	0.00	0.00	0.00
Net Cash from Investing Activities	109.37	-52.61	-60.76	-4.23	-9.94	-4.24	-1.25
Financing Activities
Debt Repayment	0.00	-17.14	0.00	29.35	0.00	0.00	0.00
Common Stock Issued	0.26	33.13	42.41	0.33	89.65	0.29	0.00
Other Financing Activities	-0.60	160.32	93.03	-0.32	100.02	0.00	34.81
Net Cash from Financing Activities	-0.34	208.77	135.44	29.36	189.67	0.29	34.81
Summary
Net Change in Cash	-26.28	45.33	13.33	-41.37	131.05	-6.97	21.04
Cash at Beginning of Period	183.72	138.39	125.06	166.44	35.39	41.76	21.32
Cash at End of Period	157.44	183.72	138.39	125.06	166.44	34.79	42.36
Free Cash Flow	-139.73	-114.65	-64.50	-70.73	-58.62	-7.26	-13.77
Supplemental Disclosures
Interest Paid	-	2.88	3.00	0.66	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About TScan Therapeutics Cash Flow

What is TScan Therapeutics's free cash flow?

TScan Therapeutics had negative free cash flow of $139.73M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$135.32M minus $4.41M of capital expenditures.

How much does TScan Therapeutics spend on capital expenditures?

TScan Therapeutics spent $4.41M on capital expenditures in fiscal 2025, compared with $3.83M a year earlier.

Does TScan Therapeutics pay dividends or buy back shares?

TScan Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition